Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Total Debt Growth (3y) (2012 - 2026)

Analysis

Charles River Laboratories International (CRL) Total Debt Growth (3y) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt Growth (3y) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn 5.11%
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn -
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn -7.70%
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -0.73%
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -13.07%
6 Evotec SE 574.75 Mn 148.87 Mn - -1.66%
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn -
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn -
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 -0.73%
Mar 28, 2026 -0.99%
Dec 27, 2025 -7.59%
Sep 27, 2025 -9.40%
Jun 28, 2025 -8.04%
Mar 29, 2025 -2.14%
Dec 28, 2024 -5.64%
Sep 28, 2024 -7.03%
Jun 29, 2024 -4.08%
Mar 30, 2024 6.45%
Dec 30, 2023 10.17%
Jul 1, 2023 5.81%
Apr 1, 2023 4.94%
Dec 31, 2022 12.76%
Sep 24, 2022 15.33%
Jun 25, 2022 13.08%
Mar 26, 2022 19.46%
Dec 25, 2021 16.92%
Sep 25, 2021 19.78%
Jun 26, 2021 14.31%